2026-04-17T11:50:32Zhttps://recercat.cat/oai/request
oai:recercat.cat:2445/662432025-12-05T09:32:09Zcom_2072_1057col_2072_478799col_2072_478917
RECERCAT author Alvarez Palomo, Ana Belen author McLenachan, Samuel author Chen, Fred K. author Da Cruz, Lyndon author Dilley, Rodney J. author Requena Osete, Jordi author Lucas, Michaela author Lucas, Andrew author Drukker, Micha author Edel, Michael John 2015-07-09T06:46:36Z2015-07-09T06:46:36Z2015-05-152015-07-09T06:46:36Z Since the discovery of induced pluripotent stem cells (iPSC) in 2006, the symptoms of many human diseases have been reversed in animal models with iPSC therapy, setting the stage for future clinical development. From the animal data it is clear that iPSC are rapidly becoming the lead cell type for cell replacement therapy and for the newly developing field of iPSC-derived body organ transplantation. The first human pathology that might be treated in the near future with iPSC is age-related macular degeneration (AMD), which has recently passed the criteria set down by regulators for phase I clinical trials with allogeneic human embryonic stem cell-derived cell transplantation in humans. Given that iPSC are currently in clinical trial in Japan (RIKEN) to treat AMD, the establishment of a set of international criteria to make clinical-grade iPSC and their differentiated progeny is the next step in order to prepare for future autologous cell therapy clinical trials. Armed with clinical-grade iPSC, we can then specifically test for their threat of cancer, for proper and efficient differentiation to the correct cell type to treat human disease and then to determine their immunogenicity. Such a rigorous approach sets a far more relevant paradigm for their intended future use than non-clinical-grade iPSC. This review focuses on the latest developments regarding the first possible use of iPSC-derived retinal pigment epithelial cells in treating human disease, covers data gathered on animal models to date and methods to make clinical-grade iPSC, suggests techniques to ensure quality control and discusses possible clinical immune responses. cc-by (c) Alvarez Palomo et al., 2015 http://creativecommons.org/licenses/by/3.0/es info:eu-repo/semantics/openAccess Teràpia cel·lular Oftalmopaties Assaigs clínics Cellular therapy Eye diseases Clinical trials Prospects for clinical use of reprogrammed cells for autologous treatment of macular degeneration info:eu-repo/semantics/article info:eu-repo/semantics/publishedVersion